Sajazir Injection
NDC Package 70709-013-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Sajazir (icatibant) injection is icatibant is used to treat sudden attacks of a certain immune system condition passed down through families called hereditary angioedema (HAE). This formulation utilizes a injection delivery system. Marketed by Cycle Pharmaceuticals Ltd-uk, this product is identified by NDC 70709-013 and is authorized under FDA application ANDA212446.

Identification & Billing

NDC Package Code
70709-013-01
Package Description
1 SYRINGE, GLASS in 1 CARTON / 3 mL in 1 SYRINGE, GLASS
Product Code
70709-013
11-Digit Billing Format
70709001301
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Sajazir
Non-Proprietary Name
Icatibant
Substance Name
Icatibant Acetate
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
ICATIBANT ACETATE 30 mg/3mL
Pharmacologic Class
Usage Information
Icatibant is used to treat sudden attacks of a certain immune system condition passed down through families called hereditary angioedema (HAE). Although this medication is not a cure for HAE, icatibant may lessen the symptoms of an attack such as rapid swelling and pain of the hands, arms, feet, legs, face, tongue, and upper airway. When attacks involve the stomach/intestines, symptoms may include abdominal pain/cramps, diarrhea, constipation, or vomiting. Attacks may happen at any time. However, stress, injury, or illness may trigger attacks in some people. Icatibant works by blocking the action of a natural substance in the body called bradykinin. Bradykinin is thought to cause the symptoms of an HAE attack.

Regulatory & Marketing

Labeler Name
Cycle Pharmaceuticals Ltd-uk
Product Type
Human Prescription Drug
FDA Application #
ANDA212446
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-03-2021
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (70709-013). Click a package code to view its specific billing and regulatory data.

70709-013-03
3 SYRINGE, GLASS in 1 CARTON / 3 mL in 1 SYRINGE, GLASS

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70709-013-01 identifies a specific commercial package of 1 syringe, glass in 1 carton / 3 ml in 1 syringe, glass of Sajazir, a human prescription drug labeled by Cycle Pharmaceuticals Ltd-uk. This injection is formulated for subcutaneous use and contains icatibant acetate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cycle Pharmaceuticals Ltd-uk on June 03, 2021. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Icatibant is used to treat sudden attacks of a certain immune system condition passed down through families called hereditary angioedema (HAE). Although this medication is not a cure for HAE, icatibant may lessen the symptoms of an attack such as rapid swelling and pain of the hands, arms, feet, legs, face, tongue, and upper airway. When attacks involve the stomach/intestines, symptoms may include abdominal pain/cramps, diarrhea, constipation, or vomiting. Attacks may happen at any time. However, stress, injury, or illness may trigger attacks in some people. Icatibant works by blocking the action of a natural substance in the body called bradykinin. Bradykinin is thought to cause the symptoms of an HAE attack.

How is this Cycle Pharmaceuticals Ltd-uk product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70709001301. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70709-013-01
11-Digit CMS (5-4-2)
70709-0013-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.